Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.52 |
| ▸ | HRH1 | P35367 | 7/20 | 0.51 |
| ▸ | HRH2 | P25021 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | USP1 | O94782 | 1/20 | 0.46 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084175 | 0.87 | HRH4 (0.47) | HRH4HRH1HRH2HRH3APP | |
| SCHEMBL14084171 | 0.87 | HRH4 (0.53) | HRH4HRH1HRH2HRH3APP | |
| SCHEMBL14084113 | 0.86 | HRH4 (0.57) | HRH4HRH1HRH2HRH3APP | |
| SCHEMBL14084104 | 0.84 | HRH4 (0.54) | HRH4HRH1HRH2HRH3APP | |
| SCHEMBL14084174 | 0.82 | HRH4 (0.45) | HRH4HRH1HRH2HRH3APP | |
| SCHEMBL14084108 | 0.82 | HRH4 (0.53) | HRH4HRH1HRH2HRH3APP | |
| SCHEMBL14084117 | 0.82 | HRH4 (0.52) | HRH4APPBCHEKDR | |
| SCHEMBL14084162 | 0.81 | HRH4 (0.53) | HRH4HRH1HRH2HRH3APP | |
| SCHEMBL602935 | 0.81 | HRH4 (0.53) | HRH4HRH1HRH2HRH3APP | |
| SCHEMBL14084161 | 0.80 | HRH4 (0.49) | HRH4HRH1HRH2HRH3BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | HRH4 3013/4885HRH1 2660/4885HRH2 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.